Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy

Oregovomab: an investigational agent for the treatment of advanced ovarian cancer

(2021) Antonella Pietragalla et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

(2020) Alessandra Battaglia et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study

(2020) Molly Brewer et al.   GYNECOLOGIC ONCOLOGY

TIMER2.0 for analysis of tumor-infiltrating immune cells

(2020) Taiwen Li et al.   NUCLEIC ACIDS RESEARCH

Role of the MUC1‐C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma

(2020) Keisuke Shigeta et al.   CANCER SCIENCE

Epithelial-Mesenchymal Transition in Cancer: A Historical Overview

(2020) Domenico Ribatti et al.   Translational Oncology

Cancer-associated mucins: role in immune modulation and metastasis

(2019) Rakesh Bhatia et al.   CANCER AND METASTASIS REVIEWS

MUC1-C INTEGRATES CHROMATIN REMODELING AND PARP1 ACTIVITY IN THE DNA DAMAGE RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER CELLS

(2019) Masaaki Yamamoto et al.   CANCER RESEARCH

GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis

(2019) Zefang Tang et al.   NUCLEIC ACIDS RESEARCH

Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

(2019) Francesca Finotello et al.   Genome Medicine

TARGETING MUC1-C INHIBITS TWIST1 SIGNALING IN TRIPLE-NEGATIVE BREAST CANCER

(2019) Tsuyoshi Hata et al.   MOLECULAR CANCER THERAPEUTICS

A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer

(2019) Alison Crawford et al.   Science Translational Medicine

Codelivery of Genistein and miRNA-29b to A549 Cells Using Aptamer-Hybrid Nanoparticle Bioconjugates

(2019) Koita Sacko et al.   Nanomaterials

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

(2019) Margaret E. Gatti‐Mays et al.   ONCOLOGIST

Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer

(2019) Marteinn Thor Snaebjornsson et al.   Cell Metabolism

Mucins: Structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets

(2018) Suresh Sulekha Dhanisha et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

A Novel Monoclonal Antibody Targets Mucin1 and Attenuates Growth in Pancreatic Cancer Model

(2018) Guang Wu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Evaluation of MUC1-Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA-29b to Nonsmall Cell Lung Cancer

(2018) Maryna Perepelyuk et al.   MOLECULAR PHARMACEUTICS

Clinical significance of MUC13 in pancreatic ductal adenocarcinoma

(2018) Sheema Khan et al.   HPB

SMAD4-independent activation of TGF-β signaling by MUC1 in a human pancreatic cancer cell line

(2018) Priyanka Grover et al.   Oncotarget

A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer

(2018) Guang Wu et al.   Theranostics

DNA Damage, Repair, and Cancer Metabolism

(2018) Marc-Olivier Turgeon et al.   Frontiers in Oncology

First-in-man study of Ad-sig-hMUC1/ecdCD40L vaccine for immunotherapy of MUC1 overexpressing epithelial cancers.

(2018) Tira Jing Ying Tan et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of MUC1-C regulates metabolism by AKT pathway in esophageal squamous cell carcinoma

(2018) Xin GongSun et al.   JOURNAL OF CELLULAR PHYSIOLOGY

A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination in ovarian cancer patients

(2017) Alessandra Battaglia et al.   IMMUNOLOGY LETTERS

Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer

(2017) Rehan Ahmad et al.   Molecular Cancer

Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma

(2017) Salvia Jain et al.   MOLECULAR CANCER THERAPEUTICS

MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer

(2017) A Bouillez et al.   ONCOGENE

MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner

(2017) Wei Jin et al.   Cell Death & Disease

Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data

(2017) Julien Racle et al.   eLife

MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer

(2017) Audrey Bouillez et al.   OncoImmunology

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

(2016) J. F. Liu et al.   ANNALS OF ONCOLOGY

Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas

(2016) Audrey Bouillez et al.   CANCER RESEARCH

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

(2016) Avery D. Posey et al.   IMMUNITY

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

(2016) Elisabeth Quoix et al.   LANCET ONCOLOGY

Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB

(2016) Micaela Morgado et al.   Oncotarget

Fundamentals of cancer metabolism

(2016) R. J. DeBerardinis et al.   Science Advances

Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

(2016) H. J. Gray et al.   Journal for ImmunoTherapy of Cancer

A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells

(2015) YUKARI NISHII et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

Immune evasion in cancer: Mechanistic basis and therapeutic strategies

(2015) Dass S. Vinay et al.   SEMINARS IN CANCER BIOLOGY

MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism

(2015) Surendra K. Shukla et al.   Oncotarget

Targeting RTK Signaling Pathways in Cancer

(2015) Tarik Regad   Cancers

Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target

(2015) Deepak Raina et al.   PLoS One

Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death

(2014) L. Yin et al.   BLOOD

Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients

(2014) Lior Carmon et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival—a substudy of the MIMOSA trial

(2014) Alexia Buzzonetti et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MUC16: molecular analysis and its functional implications in benign and malignant conditions

(2014) Dhanya Haridas et al.   FASEB JOURNAL

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

(2014) Paul LR Mitchell et al.   Journal for ImmunoTherapy of Cancer

MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells

(2013) S. Liu et al.   BLOOD

CA125/MUC16 interacts with Src family kinases, and over-expression of its C-terminal fragment in human epithelial cancer cells reduces cell–cell adhesion

(2013) Kaoru Akita et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study

(2013) Paul Sabbatini et al.   JOURNAL OF CLINICAL ONCOLOGY

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

(2013) Charles Butts et al.   LANCET ONCOLOGY

Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells

(2013) D Raina et al.   ONCOGENE

MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial–mesenchymal transition

(2013) H Rajabi et al.   ONCOGENE

MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes

(2013) S Nath et al.   Oncogenesis

Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer

(2013) John Nemunaitis et al.   Journal for ImmunoTherapy of Cancer

TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases

(2012) A Deisseroth et al.   CANCER GENE THERAPY

Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms

(2012) Lixin Zhang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study

(2012) T. Kimura et al.   Cancer Prevention Research

Abstract 762: ONT-10, a liposomal vaccine targeting hypoglycosylated MUC1, induces a potent cellular and humoral response and suppresses the growth of MUC1 expressing tumors

(2012) Linda A. Pestano et al.   CANCER RESEARCH

MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches

(2012) D W Kufe   ONCOGENE

MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer

(2012) N. V. Chaika et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

MUC1 Protein Expression in Tumor Cells Regulates Transcription of Proinflammatory Cytokines by Forming a Complex with Nuclear Factor-κB p65 and Binding to Cytokine Promoters

(2011) Sandra Cascio et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MUC13 Mucin Augments Pancreatic Tumorigenesis

(2011) S. C. Chauhan et al.   MOLECULAR CANCER THERAPEUTICS

MUC1-C Oncoprotein Regulates Glycolysis and Pyruvate Kinase m2 Activity in Cancer Cells

(2011) Michio Kosugi et al.   PLoS One

ImMucin: A novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors

(2011) Riva Kovjazin et al.   VACCINE

MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition

(2010) L D Roy et al.   ONCOGENE

CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis

(2009) Marianne Boivin et al.   GYNECOLOGIC ONCOLOGY

Deletion of the Mucin-Like Molecule Muc1 Enhances Dendritic Cell Activation in Response to Toll-Like Receptor Ligands

(2009) Marc A. Williams et al.   Journal of Innate Immunity

MUC1 oncoprotein is a druggable target in human prostate cancer cells

(2009) M. D. Joshi et al.   MOLECULAR CANCER THERAPEUTICS

MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment

(2009) S. P. Pitroda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MUC1 Oncoprotein Blocks Death Receptor-Mediated Apoptosis by Inhibiting Recruitment of Caspase-8

(2008) N. Agata et al.   CANCER RESEARCH

Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer

(2008) Jonathan Berek et al.   JOURNAL OF CLINICAL ONCOLOGY